Indacaterol (QAB149)

DRUG3 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

COPDChronic Obstructive Pulmonary Disease (COPD)Healthy

Phase 1

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

CompletedNCT00410501

NovartisHealthy

Start: 2006-12-31Target: 20Updated: 2007-06-19

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

CompletedNCT00422552

Start: 2006-09-30Target: 30Updated: 2007-06-22

Phase 3

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01202188

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2010-09-30End: 2012-03-31Updated: 2013-09-09

Related Papers

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2014-01-018 citations